Literature DB >> 7510118

Prognostic significance of histopathological subtypes in stage I pure yolk sac tumour of the ovary.

H Sasaki1, M Furusato, S Teshima, T Kiyokawa, A Tada, S Aizawa, T Yamabe, S Tsugane, Y Terashima.   

Abstract

The correlation between histological subtype [endodermal sinus (ES), polyvesicular vitelline (PV), glandular (G) and hepatoid (H) subtypes] and the prognosis of pure yolk sac tumours (YSTs) of the ovary was investigated. From 1964 to 1989, 35 patients with YSTs were treated with primary surgery and adjuvant chemotherapy. The prevalence of histological subtypes was as follows: 14 patients had a single subtype, either ES (12) or G (2); 12 patients had two subtypes, ES+G (4), ES+PV (3), ES+H (4) or G+H (1); six patients had three subtypes, ES+P+H (4) or ES+G+H (2); and three patients had all four subtypes. Multivariate analysis showed that important predictors were FIGO stage, chemotherapeutic regimen and residual tumour size. However, for stage I, multivariate analysis showed that the histological subtype was a superior predictor to the subclassification of FIGO stage I, age or chemotherapeutic regimen (P = 0.03). Kaplan-Meier analysis showed that YSTs composed of an admixture of three or four subtypes was associated with a better prognosis than those composed of one or two subtypes (P < 0.01), other variables being constant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510118      PMCID: PMC1968864          DOI: 10.1038/bjc.1994.96

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Germinal tumors exhibiting the endodermal sinus pattern of Teilum in young children.

Authors:  R W HUNTINGTON; N L MORGENSTERN; J A SARGENT; R N GIEM; A RICHARDS; K C HANFORD
Journal:  Cancer       Date:  1963-01       Impact factor: 6.860

2.  Endodermal sinus tumors of the ovary and testis. Comparative morphogenesis of the so-called mesoephroma ovarii (Schiller) and extraembryonic (yolk sac-allantoic) structures of the rat's placenta.

Authors:  G TEILUM
Journal:  Cancer       Date:  1959 Nov-Dec       Impact factor: 6.860

3.  Embryonal carcinoma of the ovary.

Authors:  R D NEUBECKER; J L BREEN
Journal:  Cancer       Date:  1962 May-Jun       Impact factor: 6.860

4.  Yolk sac differentiation in germ cell tumors. A morphologic study of 50 cases with emphasis on hepatic, enteric, and parietal yolk sac features.

Authors:  T M Ulbright; L M Roth; C A Brodhecker
Journal:  Am J Surg Pathol       Date:  1986-03       Impact factor: 6.394

5.  Chemotherapy of germ-cell ovarian tumours: first-line treatment with etoposide, bleomycin and cisplatin or carboplatin.

Authors:  E Smales; M J Peckham
Journal:  Eur J Cancer Clin Oncol       Date:  1987-05

Review 6.  Classification of endodermal sinus tumour (mesoblatoma vitellinum) and so-called "embryonal carcinoma" of the ovary.

Authors:  G Teilum
Journal:  Acta Pathol Microbiol Scand       Date:  1965

7.  Yolk sac tumors of the ovary.

Authors:  R W Huntington; W K Bullock
Journal:  Cancer       Date:  1970-06       Impact factor: 6.860

8.  Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.

Authors:  D M Gershenson; M Morris; A Cangir; J J Kavanagh; C A Stringer; C L Edwards; E G Silva; J T Wharton
Journal:  J Clin Oncol       Date:  1990-04       Impact factor: 44.544

9.  High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy.

Authors:  C R Pinkerton; J Pritchard; L Spitz
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

10.  Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases.

Authors:  R J Kurman; H J Norris
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

View more
  1 in total

1.  Prognostic value of serum α-fetoprotein in ovarian yolk sac tumors: A systematic review and meta-analysis.

Authors:  Yang-Long Guo; Ying-Li Zhang; Jian-Qing Zhu
Journal:  Mol Clin Oncol       Date:  2014-09-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.